A Phase II Study Evaluating Orteronel, an Inhibitor of Androgen Biosynthesis, in Patients With Androgen Receptor (AR)-Expressing Metastatic Breast Cancer (MBC)

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

E. Eisenhauer, P. Therasse, Jan Bogaerts et al. · European Journal of Cancer · 2008 · 29.5K citations

Medicine, Oncology, Treatment Planning +14

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies

Brian D. Lehmann, Joshua A. Bauer, Xi Chen et al. · Journal of Clinical Investigation · 2011 · 5.5K citations · Full text

Medicine, Oncology, Pharmacology +17

Phase II Trial of Bicalutamide in Patients with Androgen Receptor–Positive, Estrogen Receptor–Negative Metastatic Breast Cancer

Ayca Gucalp, Sara M. Tolaney, Steven J. Isakoff et al. · Clinical Cancer Research · 2013 · 740 citations

Medicine, Oncology, Pharmacology +16

An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen

Ashley S. Doane, Michael A. Danso, Priti Lal et al. · Oncogene · 2006 · 601 citations

Life Sciences, Molecular Biology, Oncology +14

Enzalutamide for the Treatment of Androgen Receptor–Expressing Triple-Negative Breast Cancer

Tiffany A. Traina, Kathy D. Miller, Denise A. Yardley et al. · Journal of Clinical Oncology · 2018 · 519 citations · Full text

Medicine, Oncology, Pharmacology +17